PANASONIC-CORPORATION
3.8.2020 17:49:12 CEST | Business Wire | Press release
Panasonic Corporation today announced that, in collaboration with Mayo Yasugi, Associate Professor, Department of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, it has verified the inhibitory effect of the hydroxyl radicals contained in water (nano-sized electrostatic atomized water particle) on the novel coronavirus (SARS-CoV-2).
Hydroxyl radicals contained in water are particulate ions containing hydroxyl radicals that are generated by applying a high voltage to moisture in the air. They are characterized by being strongly oxidative and highly reactive. Panasonic has been conducting research on this technology over the past 20 years since 1997, and has verified its effectiveness in a variety of areas, including inhibiting pathogenic microorganism (bacteria, fungi, and viruses) and allergens, breaking down PM 2.5 components that have adverse effects on the human body*1 .
In 2012, Panasonic conducted a virus clearance test with a third-party organization and confirmed the effectiveness of each of the 4 categories in terms of biological characteristics. Based on this result, Panasonic announced that "hydroxyl radicals contained in water" technology could be expected to have a inhibitory effect on new viruses*2 .
The novel coronavirus (SARS-CoV-2) of the current global pandemic is one such new type of virus, and testing with Osaka Prefecture University has now confirmed that the hydroxyl radicals contained in water does have an inhibitory effect on this virus. This testing was carried out in a closed laboratory environment, and was not designed to assess its efficacy in uncontrolled living spaces.
Panasonic will continue to pursue the potential of "hydroxyl radicals contained in water" technology to address possible risks associated with air pollution such as new pathogenic microorganisms, with the aim of creating healthy environments for people around the world.
For reference:
Testing of inhibitory effect of hydroxyl radicals contained in water (nano-sized electrostatic atomized water particle) on the novel coronavirus (SARS-CoV-2)
- Overview
A comparative verification was conducted in a 45L test space containing the novel coronavirus (SARS-CoV-2) with and without exposure to hydroxyl radicals contained in water.
- Results
Over 99% of novel coronavirus (SARS-CoV-2) activity was inhibited within 3 hours.
Note: This verification was designed to generate basic research data on the effects of hydroxyl radicals contained in water on the novel coronavirus in laboratory conditions different from those found in living spaces. It was not designed to evaluate product performance.
- Methodology and data
Organization: Osaka Prefecture University
Period: July, 2020
Subject: Novel coronavirus (SARS-CoV-2）
Device: "Hydroxyl radicals contained in water" generator
Method:
- "Hydroxyl radicals contained in water" generator is installed at 15cm from the floor in the 45L test space.
- A piece of gauze inoculated with the virus solution was placed in a petri dish and exposed to ”hydroxyl radicals contained in water ” for a predetermined time.
- The virus infectious titer was measured and used to calculate the inhibition rate.
- The same test was performed 3 times to confirm reproducibility.
- Results data
Test subject |
Hours |
Inhibition rate* |
|
SARS-CoV-2 |
First time |
3 hours |
99.7% |
Second time |
3 hours |
99.9% |
|
Third time |
3 hours |
99.9% |
|
*Panasonic’s calculation
Notes:
*1: Main releases on verification cases
- May 12, 2009: Positive effects of charged water particles on viruses, bacteria, and agricultural chemicals have been verified.
- October 20, 2009: The new influenza virus inhibition effect of charged water particles has been verified.
- February 20, 2012: Supression effect of charged water particles on pet-related allergens, bacteria, fungi, and viruses have been verified.
- January 16, 2014: Nano-sized electrostatic atomized water particles effectively breaks down PM2.5 components and inhibits growth of fungi attached to Yellow Sand.
*2: January 26, 2012: Virus suppression effect of charged water particles has been verified by the virus clearance test. Co-verified with Charles River Biopharmaceutical Services GmbH, a German testing organization.
About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 528 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global .
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20200803005554/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom